Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor

Thalidomide-based Immunomodulatory Drugs (IMiDs(®)), including lenalidomide and pomalidomide, are effective therapeutics for multiple myeloma. These agents have been approved with, or are under clinical development with, other targeted therapies including proteasome inhibitors, αCD38 monoclonal anti...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:PLoS One
Hoofdauteurs: North, Brian J., Almeciga-Pinto, Ingrid, Tamang, David, Yang, Min, Jones, Simon S., Quayle, Steven N.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Public Library of Science 2017
Onderwerpen:
Research Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5338861/
https://ncbi.nlm.nih.gov/pubmed/28264055
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0173507
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items